Skip to main content

MCC 20332 Activity and Enhancement of Immune Checkpoint Inhibition with Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC).

NCT04610658

Activity and Enhancement of Immune Checkpoint Inhibition with Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC).

Associated Conditions

Lung Cancer

Principal Investigator

George Simon

Sponsor

Moffitt Cancer Center

You are being asked to take part in this research study because you have small cell lung cancer (SCLC), and it has progressed after previous treatment with chemotherapy. The information in this document should help you to decide if you would like to participate.
The purpose of the first part of the study is to determine the safety and recommended dose of lurbinectedin when it is given to participants in combination with nivolumab and ipilimumab. The purpose of the second part of the study is to determine the safety and effectiveness of receiving nivolumab, ipilimumab and lurbinectedin for the treatment of relapsed or recurrent SCLC.